Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …

Highlights•Clostridioides difficile produces the toxins TcdA and TcdB, which are directly
linked to diease severity.•Toxin gene expression is influenced by a number of positive and …

Background: Microbiota-based treatments reduce the incidence of recurrent Clostridioides
difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient …

Introduction Effective treatments for recurrent Clostridioides difficile infection (rCDI) are
urgently needed. RBX2660 is an investigational microbiota-based live biotherapeutic to …

Background Fidaxomicin (FDX) has received considerable attention as a novel therapeutic
alternative agent to vancomycin (VCM) for Clostridioides difficile infection (CDI). However …

Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The
current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r …

Clostridioides difficile (C. difficile), known as the major cause of antibiotic-associated
diarrhea, is regarded as one of the most common healthcare-associated bacterial infections …

Introduction The role of the gut microbiota in health and the pathogenesis of several
diseases has been highlighted in recent years. Even though the precise mechanisms …

Purpose To study the incidence, predictors, and outcomes of diarrhea during the stay in the
intensive care unit (ICU). Methods Prospective cohort of consecutive adults in the ICU for> …

Introduction Clostridioides difficile infection (CDI) is a major healthcare problem in the
developed world, and effective management of recurrent infection remains one of the …